Chemoembolization and radioembolization for hepatocellular carcinoma

Area of Science:

• Hepatology and Interventional Oncology

Background:

• Hepatocellular carcinoma (HCC) presents a significant global health challenge.
• Curative treatments (resection, transplantation, ablation) are frequently unavailable due to advanced disease.
• Palliative options include transarterial embolization and systemic therapies.

Purpose of the Study:

• To review the current scientific understanding of embolic therapies for HCC.
• To discuss conventional and drug-eluting chemoembolization, and radioembolization.
• To cover related topics such as HCC staging, response assessment, and clinical trials.

Main Methods:

• Literature review of embolic therapies for HCC.
• Synthesis of data on chemoembolization and radioembolization.
• Discussion of HCC staging and response evaluation.

Main Results:

• Embolic therapies offer palliative treatment options for advanced HCC.
• Drug-eluting chemoembolization and radioembolization represent advancements in locoregional treatment.
• Standardized staging and response assessment are crucial for patient management.

Conclusions:

• Embolic therapies are vital palliative strategies for HCC.
• Ongoing research and clinical trials are essential for advancing HCC treatment.
• Comprehensive management involves accurate staging and response assessment.